CT characteristics of metastatic disease of the pancreas

CT characteristics of metastatic disease of the pancreas
复制标题

DOI:
10.1148/radiographics.18.2.9536484
复制
发表时间:
1998-03-01
期刊:
影响因子:
5.5
通讯作者:
Welch, TJ
Welch, TJ
中科院分区:
医学1区
文献类型:
--
作者:
Klein, KA;Stephens, DH;Welch, TJ

文献摘要

被引文献

相似文献

回顾性分析了66例胰腺转移瘤患者10年内的造影剂增强计算机断层扫描(CT)结果。最常见的原发肿瘤是肾细胞癌(30.3%)和支气管癌(22.7%)。转移显示没有偏好任何特定的胰腺部分。大部分(75.8%)转移瘤为边缘不连续的肿瘤,多为圆形或卵圆形,边缘光滑。超过四分之三的病变表现出增强(通常是不均匀的)。血管受累不常见。在原发性肿瘤确诊后一段时间发现胰腺转移的患者中,间隔时间范围为2至295个月,最长的平均间隔时间(120.2个月)与肾细胞癌转移性肿瘤相关。这些肿瘤在CT上的表现主要是高密度肿块,常伴有非强化的内部成分,与原发性肾细胞癌相似。然而,在大多数胰腺转移瘤中,临床信息结合CT特征,如肿瘤的多样性或血管丰富,可以将转移瘤与原发性肿瘤鉴别。当胰腺肿瘤的诊断不确定时,经皮穿刺活检通常允许肿瘤类型的组织学确认。
Contrast material-enhanced computed tomographic (CT) scans obtained over a 10-year period in 66 patients with metastases to the pancreas were retrospectively reviewed. The primary tumors most commonly responsible for these metastases were renal cell carcinoma (30.3%) and bronchogenic carcinoma (22.7%). Metastases showed no predilection for any particular part of the pancreas. The majority (75.8%) of metastases appeared as tumors with discrete margins, and most of these tumors were round or ovoid with smooth borders. Over three-fourths of the lesions demonstrated enhancement (usually heterogeneous). Vascular involvement was uncommon. In those patients in whom pancreatic metastases were discovered some time after the primary tumor was identified, the interval ranged from 2 to 295 months, with the longest mean interval (120.2 months) being associated with metastatic tumors from renal cell carcinoma. The appearance of these tumors at CT-predominantly hyperattenuating masses, often with nonenhancing internal components-was similar to that of primary renal cell carcinoma. In most pancreatic metastases, however, clinical information in conjunction with CT characteristics such as multiplicity of tumors or hypervascularity permit differentiation of metastases from primary neoplasm. When diagnosis of a pancreatic neoplasm is uncertain, percutaneous biopsy often permits histologic confirmation of the tumor type.